{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:23:22Z","timestamp":1782476602982,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"DOI":"10.7759\/cureus.108086","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T09:34:26Z","timestamp":1777628066000},"source":"Crossref","is-referenced-by-count":1,"title":["Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy With Subsequent Diagnosis of Mantle Cell Lymphoma"],"prefix":"10.7759","author":[{"given":"Chuchu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Duffield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahtiyar","family":"Toz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e328364e9d9","article-title":"Acquired necrotizing myopathies","volume":"26","author":"Allenbach Y","year":"2013","unstructured":"Allenbach Y, Benveniste O. Acquired necrotizing myopathies. Curr Opin Neurol. 2013, 26:554-560. 10.1097\/WCO.0b013e328364e9d9","journal-title":"Curr Opin Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen AL","year":"2011","unstructured":"Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, Casciola-Rosen LA. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011, 63:713-721. 10.1002\/art.30156","journal-title":"Arthritis Rheum"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf238","article-title":"The incidence of anti-HMGCR immune-mediated necrotizing myopathy: an Australian and UK retrospective multi-site cohort study","volume":"64","author":"Khoo T","year":"2025","unstructured":"Khoo T, Tan E, Limaye V, et al.. The incidence of anti-HMGCR immune-mediated necrotizing myopathy: an Australian and UK retrospective multi-site cohort study. Rheumatology (Oxford). 2025, 64:4995-5003. 10.1093\/rheumatology\/keaf238","journal-title":"Rheumatology (Oxford)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach Y","year":"2016","unstructured":"Allenbach Y, Keraen J, Bouvier AM, et al.. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain. 2016, 139:2131-2135. 10.1093\/brain\/aww054","journal-title":"Brain"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000290","article-title":"Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy","volume":"3","author":"Kadoya M","year":"2016","unstructured":"Kadoya M, Hida A, Hashimoto Maeda M, et al.. Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy. Neurol Neuroimmunol Neuroinflamm. 2016, 3:e290. 10.1212\/NXI.0000000000000290","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2022.101771","article-title":"Cancer and myositis: who, when, and how to screen","volume":"36","author":"Kardes S","year":"2022","unstructured":"Kardes S, Gupta L, Aggarwal R. Cancer and myositis: who, when, and how to screen. Best Pract Res Clin Rheumatol. 2022, 36:101771. 10.1016\/j.berh.2022.101771","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01045-w","article-title":"International guideline for idiopathic inflammatory myopathy-associated cancer screening: an International Myositis Assessment and Clinical Studies\u00a0Group (IMACS)\u00a0initiative","volume":"19","author":"Oldroyd AG","year":"2023","unstructured":"Oldroyd AG, Callen JP, Chinoy H, et al.. International guideline for idiopathic inflammatory myopathy-associated cancer screening: an International Myositis Assessment and Clinical Studies\u00a0Group (IMACS)\u00a0initiative. Nat Rev Rheumatol. 2023, 19:805-817. 10.1038\/s41584-023-01045-w","journal-title":"Nat Rev Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac144","article-title":"Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation","volume":"62","author":"Shelly S","year":"2022","unstructured":"Shelly S, Beecher G, Milone M, et al.. Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation. Rheumatology (Oxford). 2022, 62:281-289. 10.1093\/rheumatology\/keac144","journal-title":"Rheumatology (Oxford)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nlaa006","article-title":"Anti-HMGCR antibody-positive myopathy shows Bcl-2-positive inflammation and lymphocytic accumulations","volume":"79","author":"Kurashige T","year":"2020","unstructured":"Kurashige T, Murao T, Mine N, et al.. Anti-HMGCR antibody-positive myopathy shows Bcl-2-positive inflammation and lymphocytic accumulations. J Neuropathol Exp Neurol. 2020, 79:448-457. 10.1093\/jnen\/nlaa006","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000832","article-title":"Anti-HMGCR myopathy: clinical and histopathological features, and prognosis","volume":"33","author":"Kurashige T","year":"2021","unstructured":"Kurashige T. Anti-HMGCR myopathy: clinical and histopathological features, and prognosis. Curr Opin Rheumatol. 2021, 33:554-562. 10.1097\/BOR.0000000000000832","journal-title":"Curr Opin Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2009.09.003","article-title":"Myopathy secondary to intravascular large B-cell lymphoma","volume":"19","author":"Marini-Bettolo C","year":"2009","unstructured":"Marini-Bettolo C, Lane R, Charles P, et al.. Myopathy secondary to intravascular large B-cell lymphoma. Neuromuscul Disord. 2009, 19:856-859. 10.1016\/j.nmd.2009.09.003","journal-title":"Neuromuscul Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.47.4.1009","article-title":"Angiotropic large-cell lymphoma with peripheral nerve and skeletal muscle involvement: early diagnosis and treatment","volume":"47","author":"Levin KH","year":"1996","unstructured":"Levin KH, Lutz G. Angiotropic large-cell lymphoma with peripheral nerve and skeletal muscle involvement: early diagnosis and treatment. Neurology. 1996, 47:1009-1011. 10.1212\/wnl.47.4.1009","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10091","article-title":"Intravascular lymphomatosis","volume":"25","author":"Oei ME","year":"2002","unstructured":"Oei ME, Kraft GH, Sarnat HB. Intravascular lymphomatosis. Muscle Nerve. 2002, 25:742-746. 10.1002\/mus.10091","journal-title":"Muscle Nerve"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510x(95)00324-u","article-title":"Inflammatory neuromuscular disorders associated with chronic lymphoid leukemia: evidence for clonal B cells within muscle and nerve","volume":"137","author":"Creange A","year":"1996","unstructured":"Creange A, Theodorou I, Sabourin JC, Vital C, Farcet JP, Gherardi RK. Inflammatory neuromuscular disorders associated with chronic lymphoid leukemia: evidence for clonal B cells within muscle and nerve. J Neurol Sci. 1996, 137:35-41. 10.1016\/0022-510x(95)00324-u","journal-title":"J Neurol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2016.08.060","article-title":"Inflammatory myopathies and lymphoma","volume":"369","author":"St\u00fcbgen JP","year":"2016","unstructured":"St\u00fcbgen JP. Inflammatory myopathies and lymphoma. J Neurol Sci. 2016, 369:377-389. 10.1016\/j.jns.2016.08.060","journal-title":"J Neurol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1126\/science.1246886","article-title":"Association of the autoimmune disease scleroderma with an immunologic response to cancer","volume":"343","author":"Joseph CG","year":"2014","unstructured":"Joseph CG, Darrah E, Shah AA, et al.. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014, 343:152-157. 10.1126\/science.1246886","journal-title":"Science"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011501","article-title":"Anti-NXP2-antibody-positive immune-mediated necrotizing myopathy associated with acute myeloid leukemia: a case report","volume":"97","author":"Su L","year":"2018","unstructured":"Su L, Yang Y, Jia Y, Liu X, Zhang W, Yuan Y, Li Z. Anti-NXP2-antibody-positive immune-mediated necrotizing myopathy associated with acute myeloid leukemia: a case report. Medicine (Baltimore). 2018, 97:e11501. 10.1097\/MD.0000000000011501","journal-title":"Medicine (Baltimore)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00355-6","article-title":"Treatment approaches for patients with TP53-mutated mantle cell lymphoma","volume":"10","author":"Lew TE","year":"2023","unstructured":"Lew TE, Minson A, Dickinson M, et al.. Treatment approaches for patients with TP53-mutated mantle cell lymphoma. Lancet Haematol. 2023, 10:142-154. 10.1016\/S2352-3026(22)00355-6","journal-title":"Lancet Haematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue MH","year":"2015","unstructured":"Delfau-Larue MH, Klapper W, Berger F, et al.. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015, 126:604-611. 10.1182\/blood-2015-02-628792","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/483264-anti-3-hydroxy-3-methylglutaryl-coenzyme-a-reductase-hmgcr-immune-mediated-necrotizing-myopathy-with-subsequent-diagnosis-of-mantle-cell-lymphoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T09:34:26Z","timestamp":1777628066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/483264-anti-3-hydroxy-3-methylglutaryl-coenzyme-a-reductase-hmgcr-immune-mediated-necrotizing-myopathy-with-subsequent-diagnosis-of-mantle-cell-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.108086","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}